StockNews.com started coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Free Report) in a report released on Friday morning. The firm issued a sell rating on the stock.
Separately, Alliance Global Partners boosted their price objective on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a buy rating in a research report on Monday, July 22nd.
View Our Latest Stock Report on TNXP
Tonix Pharmaceuticals Price Performance
Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($5.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($16.64) by $10.88. The company had revenue of $2.48 million during the quarter, compared to analyst estimates of $4.00 million. Equities research analysts expect that Tonix Pharmaceuticals will post -34.73 earnings per share for the current fiscal year.
Institutional Trading of Tonix Pharmaceuticals
An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its holdings in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) by 160.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,770,000 shares of the company’s stock after purchasing an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned approximately 14.09% of Tonix Pharmaceuticals worth $1,519,000 at the end of the most recent quarter. 82.26% of the stock is owned by institutional investors.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Articles
- Five stocks we like better than Tonix Pharmaceuticals
- What Makes a Stock a Good Dividend Stock?
- MarketBeat Week in Review – 8/5 – 8/9
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Profitably Trade Stocks at 52-Week Highs
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.